In October 2025, the 17th World Stroke Congress (WSC 2025) , ​​becoming the largest and most significant international forum in this field. More than 4,000 delegates from 100 countries—leading neurologists, neurosurgeons, rehabilitation specialists, researchers, and patient advocates—united under the auspices of the World Stroke Organization (WSO) to define the future of stroke prevention, treatment, and rehabilitation. The data presented on the role of antioxidant therapy was of particular interest.

We wish you a Merry Christmas and a Happy New Year 2026! May the new year bring you confidence in the future, professional inspiration, and sustainable results in your daily clinical practice. Thank you for your trust and cooperation, your commitment to evidence-based approaches, and your commitment to finding optimal solutions for each patient.

Happy Neurologist's Day, dear colleagues!

We sincerely congratulate you on your professional holiday!

On World Stroke Day, it is important to remember that stroke is a global medical and social problem in Russia and worldwide due to its high prevalence, disabling consequences, and high mortality rates.

Timely diagnosis, adequate treatment, and intensive rehabilitation are essential; they can significantly reduce the consequences of stroke and improve patients' quality of life. Prevention and a healthy lifestyle are key to reducing the risk of stroke and its complications.

From March 9 to March 15, the World Wide Week Week is held around the world, aimed at increasing the awareness of the disease, which remains one of the leading causes of irreversible blindness. Glaucoma is a chronic progressive disease of the optic nerve, requiring a comprehensive approach to treatment.

Scientists from the national center of cardiovascular diseases in Beijing compared the effectiveness of a decrease in systolic pressure levels to 120 mm Hg. and up to 140 mm Hg. The results of the ESPRIT study were presented at the scientific session of the American AHA-2023 Association and published on the Medscape portal.

Neuroprotection should serve as an integral part of patients with AG. It is recommended to supplement the algorithm for drug treatment of patients with hypertension by turning on ethylmethylhydroxypyridine of succinate (Mexidol ^® ) in the clinical recommendations “Arterial hypertension in adults” (i10/i11/i12/i13/i15, according to ICD-10).

NPK Farmasoft LLC reports on the inclusion of a new indication - attention deficit syndrome in children (age from 6 years), including hyperactivity, impaired attention, impulsivity - in the instructions for the medical use of the drug Mexidol ^® tablets covered film shell, 125 mg. "

Dear colleagues, we inform you about the inclusion of a new indication - attention deficit syndrome with hyperactivity (ADHD) in children aged 6 to 12 years, including hyperactivity, impaired attention, impulsiveness.

With the high -speed rhythm of life that is now, many patients, especially working age, do not always manage to find time in their dense schedule for visiting the procedural office. Nevertheless, they also get sick and they can also diagnose serious pathologies that will require the purpose of the course of effective therapy, including Injection forms.

Influenza is an acute infectious disease that affects both the upper and lower respiratory tract, the causative agent of which is the virus.

In the “Library” , the “evidence base” posts the article “Results of a multicenter dual blind randomized placebo-controlled clinical study on assessing the effectiveness and safety of the drug Mexidol in the treatment of a deficiency of attention with hyperactivity in children (mega)”.

The results of an international multicenter randomized double-blind-controlled study of the efficiency and safety of sequential therapy of patients with chronic brain ischemia drugs Mexidol ^® and Mexidol ^® Forte 250 (study of Memo) conducted in full accordance with the international ethical and scientific research standard and conducting research with the participation Man (GCP), published in the journal of neurology and psychiatry named after S.S. Korsakova, 2021; 121 (11): 7–16., The host of the Higher Attestation Commission - a reviewed publication for neurologists and psychiatrists of Russia.

In order to fully disclose the therapeutic potential of the drug Mexidol ^®, it is consistent long -term therapy (randomized clinical examination of Epica ¹ , 2017): first 14 days of injection (saturation phase), with the subsequent transition to a tablet form of Mexidol ^® or Mexol ^® 250 V. the course of 2 months (phase of maximization of the therapeutic effect). The frequency of therapy is 2-3 times a year or during periods of exacerbations.